{
    "root": "2f836bf8-7034-db2e-e063-6394a90a3a3e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FESOTERODINE FUMARATE",
    "value": "20250304",
    "ingredients": [
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "HYPROMELLOSE 2208 (100 MPA.S)",
            "code": "B1QE5P712K"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2208 (100000 MPA.S)",
            "code": "VM7F0B23ZI"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "FESOTERODINE FUMARATE",
            "code": "EOS72165S7"
        }
    ],
    "indications": "Fesoterodine fumarate extended-release tablets are indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. (1.2)",
    "contraindications": "• OAB in Adults: The recommended starting dosage is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of 8 mg once daily. ( 2.1 ) • NDO in Pediatric Patients 6 Years and Older: • Pediatric Patients Weighing Greater than 25 kg and up to 35 kg: The recommended dosage is 4 mg orally once daily. If needed, dosage may be increased to 8 mg orally once daily. ( 2.2 ) • Pediatric Patients Weighing Greater than 35 kg: The recommended starting dosage is 4 mg orally once daily. After one week, increase to 8 mg orally once daily. ( 2.2 ) • Adult or Pediatric Patients with Renal Impairment: Refer to the full prescribing information for recommended dosage. ( 2.3 , 2.4 ) • Dosage Modifications Due to Strong CYP3A4 Inhibitors: Refer to the full prescribing information for recommended dosage. ( 2.5 ) • Administration: Swallow whole with liquid. Do not chew, divide, or crush. Take with or without food. ( 2.6 )",
    "warningsAndPrecautions": "Fesoterodine fumarate extended-release tablets 4 mg are light blue, oval, biconvex, film coated tablets debossed with 'H' on one side and 'F6' on the other side. They are supplied as follows: \n  \n                       Bottles of 30 tablets                 NDC 31722-033-30 \n    Bottles of 90 tablets                 NDC 31722-033-90 \n  \n                       Fesoterodine fumarate extended-release tablets 8 mg are blue, oval, biconvex, film coated tablets debossed with 'H' on one side and 'F7' on the other side. They are supplied as follows: \n  \n                       Bottles of 30 tablets                NDC 31722-034-30 \n    Bottles of 90 tablets                NDC 31722-034-90 \n  \n                       Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions": "Fesoterodine fumarate extended-release tablets are contraindicated in patients with any of the following: \n    · known or suspected hypersensitivity to fesoterodine fumarate extended-release tablets or any of its ingredients, or to tolterodine tartrate tablets or tolterodine tartrate extended-release capsules\n \n  [see Clinical Pharmacology (\n  \n   12.1)]\n \n  . Reactions have included angioedema\n \n  [see Warnings and Precautions (\n  \n   5.1)]\n \n  \n                       · urinary retention\n \n  [see Warnings and Precautions (\n  \n   5.2)]\n \n  \n                       · gastric retention\n \n  [see Warnings and Precautions (\n  \n   5.3)]\n \n  \n                       · uncontrolled narrow-angle glaucoma\n \n  [see Warnings and Precautions (\n  \n   5.4)]"
}